Literature DB >> 8257153

Antibacterial activities of OPC-17116, ofloxacin, and ciprofloxacin against 200 isolates of Neisseria gonorrhoeae.

J M Zenilman1, T Neumann, M Patton, C Reichart.   

Abstract

OPC-17116 is a new fluoroquinolone with potent activity against aerobic and anaerobic organisms. We evaluated the susceptibilities of 200 clinical gonococcal isolates including organisms with plasmid and chromosomally mediated resistance to beta-lactams and tetracycline. The antibiotics studied included OPC-17116, ofloxacin, ciprofloxacin, penicillin, tetracycline, erythromycin, azithromycin, and ceftriaxone. All isolates tested were susceptible to the quinolone class of antibiotics. The MICs of ciprofloxacin, ofloxacin, and OPC-17116 for 90% of isolates tested were 0.004, 0.03, and 0.004 micrograms/ml, respectively. For organisms with chromosomally mediated resistance to penicillin and tetracycline, geometric mean MICs of all antibiotics including the quinolones were increased.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8257153      PMCID: PMC192260          DOI: 10.1128/AAC.37.10.2244

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  4 in total

1.  National surveillance of antimicrobial resistance in Neisseria gonorrhoeae. The Gonococcal Isolate Surveillance Project.

Authors:  S K Schwarcz; J M Zenilman; D Schnell; J S Knapp; E W Hook; S Thompson; F N Judson; K K Holmes
Journal:  JAMA       Date:  1990-09-19       Impact factor: 56.272

Review 2.  Therapy for gonococcal infections: options in 1989.

Authors:  J S Moran; J M Zenilman
Journal:  Rev Infect Dis       Date:  1990 Jul-Aug

3.  Standardization of disk diffusion and agar dilution susceptibility tests for Neisseria gonorrhoeae: interpretive criteria and quality control guidelines for ceftriaxone, penicillin, spectinomycin, and tetracycline.

Authors:  R N Jones; T L Gavan; C Thornsberry; P C Fuchs; E H Gerlach; J S Knapp; P Murray; J A Washington
Journal:  J Clin Microbiol       Date:  1989-12       Impact factor: 5.948

4.  Temporal trends in gonococcal antibiotic resistance in Baltimore.

Authors:  C A Reichart; T Neumann; P Foreman; J M Zenilman; E W Hook
Journal:  Sex Transm Dis       Date:  1992 Jul-Aug       Impact factor: 2.830

  4 in total
  6 in total

1.  Comparison of single-dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in men. The STD Study Group.

Authors:  E W Hook; W M McCormack; D Martin; R B Jones; K Bean; A N Maroli
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

2.  Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males.

Authors:  C Efthymiopoulos; S L Bramer; A Maroli
Journal:  Clin Pharmacokinet       Date:  1997       Impact factor: 6.447

Review 3.  Grepafloxacin.

Authors:  A J Wagstaff; J A Balfour
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

4.  Activities of three investigational fluoroquinolones (BAY y 3118, DU-6859a, and clinafloxacin) against Neisseria gonorrhoeae isolates with diminished susceptibilities to ciprofloxacin and ofloxacin.

Authors:  C J Carlyn; L J Doyle; C C Knapp; M D Ludwig; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1995-07       Impact factor: 5.191

5.  Daily oral grepafloxacin vs. twice daily oral doxycycline in the treatment of Chlamydia trachomatis endocervical infection.

Authors:  W M McCormack; D H Martin; E W Hook; R B Jones
Journal:  Infect Dis Obstet Gynecol       Date:  1998

6.  Grepafloxacin versus cefixime as single-dose therapy for uncomplicated gonorrhea in women.

Authors:  T F Mroczkowski; E W Hook Iii; R B Jones; W M McCormack; D H Martin
Journal:  Infect Dis Obstet Gynecol       Date:  1997
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.